AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02167321
Drug: Arm B : adjuvant FOLFOX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
Trial: NCT01127620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encapsulated tablets
Trial: NCT00882024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, bid, 12 weeks
Trial: NCT03381287
Drug: HTD1801 Tablets, 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day (250 mg BID)
Trial: NCT03381287
Drug: HTD1801 Tablets, 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day (500 mg BID)
Trial: NCT03381287
Drug: HTD1801 Tablets, 2000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg/day (1000 mg BID)
Trial: NCT03381287
Drug: Placebo to match 500 mg HTD1801
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/day (1 tablet BID)
Trial: NCT03381287
Drug: Placebo to match 1000 mg HTD1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets/day (2 tablet BID)
Trial: NCT03381287
Drug: Placebo to match 2000 mg HTD1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets/day (4 tablet BID)
Trial: NCT00953706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02015780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam placebo-matching tablets
Trial: NCT02015780
Drug: Antihyperglycemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
Trial: NCT00000278
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01195428
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily
Trial: NCT01195428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00660582
Drug: Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given in combination day 1 and 2, every second week, 8 cycles
Trial: NCT00775255
Drug: clarithromycin 250 mg/5 mL powder for oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01101529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered instead of Emend
Trial: NCT02175186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03672630
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
Trial: NCT02122380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo pill by mouth per day for 30 days
Trial: NCT01783444
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
Trial: NCT02710539
Drug: perindopril, indapamide , amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
Trial: NCT02710539
Drug: Tripliam (perindopril, indapamide, amlodipine)
RxNorm normalized name: indapamide / perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
Trial: NCT00960544
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
Trial: NCT01581684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for oral administration
Trial: NCT01628913
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 400 mg bid p.o. (by mouth, twice daily)
Trial: NCT01248793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
Trial: NCT00638729
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert tablet p.o., 60-90 min prior to estimated induction time
Trial: NCT02580877
Drug: 67.5 mg oral insulin crystals daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human insulin crystals in capsules
Trial: NCT02580877
Drug: 500mg oral insulin crystals every other week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human insulin crystals in capsules
Trial: NCT00980148
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FDA approved, a 1 gm single dose, two 500 mg tablets.
Trial: NCT00980148
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved, a 100 mg capsule twice a day for 7 days.
Trial: NCT00052910
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00052910
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00940550
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tablet, once.
Trial: NCT00940550
Drug: Placebo to match melatonin, zolpidem and temazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
Trial: NCT02089932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02559635
Drug: Nestle Resource
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
Trial: NCT03204760
Drug: Prednisolone Oral, Per 5 Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
Trial: NCT03579758
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02663154
Drug: Saline inhaler
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
Trial: NCT02665533
Drug: Diclofenac Sodium associated with Codeine
RxNorm normalized name: codeine / diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac Sodium 50 mg associated with Codeine 50 mg
Trial: NCT03692403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01342731
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
Trial: NCT01861847
Drug: 7-Keto Dehydroepiandrosterone
RxNorm normalized name: 7-keto-dehydroepiandrosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Trial: NCT01861847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
Trial: NCT00003365
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01469039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for IM injection, given monthly
Trial: NCT00698828
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily subcutaneous injections of placebo for 12 weeks.
Trial: NCT00698828
Drug: SUN11031 20 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
Trial: NCT00698828
Drug: SUN11031 40 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
Trial: NCT03165955
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
Trial: NCT03346525
Drug: intramuscular benzathine penicillin G (BPG) prophylaxis
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
Trial: NCT02550444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Trial: NCT00537472
Drug: Low dose bupivicaine in spinal anesthetic
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 9 mg intrathecal single shot injection at start of surgery
Trial: NCT02398526
Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage and treatment duration according to the decision of the treating physician
Trial: NCT00041028
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00210847
Drug: tramadol, acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04686344
Drug: intermittent boluses of Hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent boluses every 6 hours over 30 min for 48 hours
Trial: NCT04686344
Drug: continuous infusion of Hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion over a period of 48 hours
Trial: NCT00107276
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00107276
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03962855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
Trial: NCT01595087
Drug: Osteodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
Trial: NCT03856866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
Trial: NCT01459094
Drug: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
Trial: NCT01459094
Drug: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
Trial: NCT04231448
Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
Trial: NCT04231448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
Trial: NCT03433976
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia for planned cesarean sections
Trial: NCT01881789
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
Trial: NCT03965845
Drug: Telaglenestat (CB-839)
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
Trial: NCT02379052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00465673
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m2 over 1 hour infusion for 21 days
Trial: NCT02058979
Drug: CONTINUOUS INFUSION (Ancef)
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Infusion of ANCEF with infusion pump
Trial: NCT02092181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
Trial: NCT00956293
Drug: Enteric Coated Mycophenolic Acid (MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
Trial: NCT00956293
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
Trial: NCT00956293
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Trial: NCT00920556
Drug: 5.0g SRT501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
Trial: NCT01299389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
Trial: NCT01220492
Drug: conventional plus MSC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
Trial: NCT01220492
Drug: conventional plus placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
Trial: NCT02412150
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
Trial: NCT02412150
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
Trial: NCT02170844
Drug: Placebo of BIBR 1048 MS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01741922
Drug: Acetylsalicylic morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
Trial: NCT03507127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
Trial: NCT01011114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
Trial: NCT05908838
Drug: Modified Banxia Xiexin Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
Trial: NCT05908838
Drug: combination chemotherapy with Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination chemotherapy with Placebo granules
Trial: NCT01044030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mL by mouth three times daily
Trial: NCT02625181
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Analgesic drug / Opioid
Trial: NCT02625181
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic drug / Opioid
Trial: NCT02625181
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic drug / Opioid
Trial: NCT02625181
Drug: Oxymorphone
RxNorm normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic drug / Opioid
Trial: NCT02625181
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic drug / Opioid